Cargando…
Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration
Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique formulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, a...
Autores principales: | Rojekar, Satish, Pallapati, Anusha R, Gimenez-Roig, Judit, Korkmaz, Funda, Sultana, Farhath, Sant, Damini, Haeck, Clement M, Macdonald, Anne, Kim, Se-Min, Rosen, Clifford J, Barak, Orly, Meseck, Marcia, Caminis, John, Lizneva, Daria, Yuen, Tony, Zaidi, Mone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325703/ https://www.ncbi.nlm.nih.gov/pubmed/37334968 http://dx.doi.org/10.7554/eLife.88898 |
Ejemplares similares
-
Development and Biophysical Characterization of a Humanized FSH–Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra–High Concentration
por: Rojekar, Satish, et al.
Publicado: (2023) -
SAT669 Development And Biophysical Characterization Of A Humanized FSH-blocking Monoclonal Antibody Therapeutic Formulated At An Ultra-high Concentration
por: Rojekar, Satish, et al.
Publicado: (2023) -
SAT668 Can We Treat Osteoporosis, Obesity And Neurodegeneration With A Single FSH-blocking Drug?
por: Rani Pallapati, Anusha Rani, et al.
Publicado: (2023) -
SAT649 Org43553, The First Low-molecular-weight Agonist Of The Human Luteinizing Hormone Receptor Induces Leanness And Energy Expenditure In Mice
por: Lizneva, Daria, et al.
Publicado: (2023) -
Bone circuitry and interorgan skeletal crosstalk
por: Zaidi, Mone, et al.
Publicado: (2023)